Mcneil Ab

Ortho-Mcneil Pharmaceutical Corp.

Cordis Corporation

Ortho Pharmaceutical Corporation

Other

Janssen Pharmaceutica Nv

Biocryst Pharmaceuticals, Inc.

Mcneil Pharmaceutical, Inc.

Cynthia Anne Maryanoff

Ahmed F Abdel-Magid

Frank John Villani, Jr

Allen B Reitz

Robin C Stanzione

William V Murray

Kirk L Sorgi

Xiaobing Li

James N Plampin

Bruce E Maryanoff

Bruce D Harris

Linda K Jolliffe

Virginia L Pulito

Linda Mulcahy

Adrian Thaler

Urs Eggmann

Gee-Hong Kuo

David F McComsey

Gerard H Llanos

Haripada Khatuya

Catherine P Prouty

Malcolm K Scott

Hua M Zhong

Steven Mehrman

Max Rey

Judith Cohen

Richard H Hutchings

Karel Six

Nelson C F Yim

William L Rion

Dennis C Liotta

Penina Feibush

Robert B Raffa

Roy A Olofson

Cynthia L Fedde

John E Mills

Thomas W Adkins

Thomas W Schultz

Vasken Paragamian

Cheryl P Kordik

Lorraine Scott

Daniel J Korey

George Papandreou

Frank J Villani, Jr

Judith Hope Cohen

Walter E Stalzer

Charles F Cicco

David A Cherry

James D Rodgers

Lori Alquier

Vladimir Veselov

Gail Reed

Gyorgy Vas

Eugena A Akerman

Dirk Cleeren

Fridtjof Schr&ouml;der

Roger Vandecruys

Donald A Koch

Karin Maria Balss

Thomas L Todd

William Rion

Georgios Papandreou

Sebastiano Mattei

Erja A Lehto

Gunther G Laufer

Armin R&ouml;ssler

Michael Justus

Christian Weh

Gregor Welti

The invention relates to improved liquid phase processes for the preparation of the 21 residue protein component, (Lys-Leu)-Lys, of the pulmonary surfactant KL-4. These process are amenable to large scale synthesis and one process employs a method of saponifying an ester which reduces the inherent racemization of the &#x3b1;-carbon.

Liquid phase peptide synthesis of KL-4 pulmonary surfactant

Holding devices for securely holding medical devices, such as stents, are utilized in performing molecular imaging of the medical devices.

Sample plate designs for MALDI and DESI for molecular imaging of coated medical devices on the applied biosystems Qstar/Voyager MALDI mass spectrometer

Processes for coating implantable medical devices that improve the stability of therapeutic agents contained within the coating.

Method of coating stents

The present invention is directed to novel compounds of the formula (I)  wherein X, R, R, R, R, Rand Rare as described in the specification, processes for the preparation of and pharmaceutical compositions comprising said derivatives. The compounds of the present invention are useful for the treatment of epilepsy. The invention is further directed to a process for the preparation of compounds of formula (XX),  wherein X, R, R, Rand Rare as described in the specification.

Substituted sulfamate anticonvulsant derivatives

A method and system for the non-destructive analysis of medical devices uses a confocal Raman microscope and other non-destructive analytical tools to assess the spatial distribution of components of an object such as the distribution of an active pharmaceutical ingredient (API) within a polymer matrix. In a preferred embodiment, confocal Raman spectroscopy was used to differentiate each component found in the sirolimus-eluting coronary stent. The unique spectral features identified for each component were then used to develop three separate calibration curves to describe the solid phase distribution found on drug-polymer coated stents. The calibration curves were obtained by analyzing confocal Raman spectral depth profiles from a set of 16 unique formulations of drug-polymer coatings sprayed onto stents and planar substrates.

System and method for the non-destructive assessment of the quantitative spatial distribution of components of a medical device

An improved process for coating implantable medical devices utilizes a number of techniques for improving the stability of therapeutic agents contained within the coating. The stability of the therapeutic agents may be improved by creating substantially solvent-free, amorphous forms of the therapeutic agents.

Solvent free amorphous rapamycin

A process for making a compound of formula I wherein the substituents are as described in the specification comprising reacting a ketone of formula II with succinic anhydride and an alkoxide base to form a compound of formula III which is reacted with a compound of formula IV to form a compound of V and reacting with an alcohol to form the corresponding ester of formula VI and reacting the ester with N-methylhydroxylamine.

Process for preparing 1,5-diaryl-3-substituted pyrazoles

The present invention is directed to a continuous process for the preparation of fructopyranose sulfamate derivatives of the general formula (I) 

Continuous process for the preparation of fructopyranose sulfamate derivatives

The invention relates to novel pharmaceutically acceptable salts of anticonvulsant derivatives, processes for preparation of and pharmaceutical compositions containing said salts, useful in the treatment of epilepsy.

Anticonvulsant derivative salts

The present invention is directed to novel compounds of the formula (I)  The invention is further directed to a process for the preparation of compounds of formula (XX), 

A process for making a compound of formula I wherein the substituents are as described in the specification comprising reacting a ketone of formula II with succinic anhydride and an alkoxide base to form a compound of formula IIIwhich is reacted with a compound of formula IV to form a compound of Vand reacting with an alcohol to form the corresponding ester of formula VIand reacting the ester with N-methylhydroxylamine.

This invention relates to a series of arylsubstituted piperazines, of Formula Ipharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the &#x3b1;-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this and other disease.

Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia

This invention relates a to a series of heterocyclic substituted piperazines of Formula Ipharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the &#x3b1;-adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this disease.

Heterocycles useful in the treatment of benign prostatic hyperplasia

Process for preparing 1, 5-diaryl-3-substituted pyrazoles

Growing community of inventors

New Hope, PA, United States of America

Cynthia Anne Maryanoff